Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021
May 11 2021 - 7:00AM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that it will report its first quarter 2021
financial results on Monday, May 17, 2021.
Altimmune management will host a conference call
for investors beginning at 8:30 am E.T. to discuss the first
quarter 2021 financial results and provide a business
update.
Conference Call
Information:
|
Date: |
Monday, May 17, 2021 |
|
Time: |
8:30 am Eastern Time |
|
Domestic Dial-in: |
877-423-9813 |
|
International Dial-in: |
201-689-8573 |
|
Conference ID: |
13719206 |
|
Webcast: |
http://public.viavid.com/index.php?id=144634 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical
company focused on developing intranasal vaccines, immune
modulating therapies and treatments for liver disease. Our diverse
pipeline includes proprietary intranasal vaccines for COVID-19
(AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an
intranasal immune modulating therapeutic for COVID-19 (T-COVID™);
and next generation peptide therapeutics for NASH (ALT-801) and
chronic hepatitis B (HepTcell™). For more information on Altimmune,
please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Investor & Media Contacts:
|
Will Brown |
Stacey Jurchison |
|
Chief Financial Officer |
Sr. Dir, Investor Relations |
|
Phone: 240-654-1450 |
Phone : 410-474-8200 |
|
wbrown@altimmune.com |
sjurchison@altimmune.com |
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Apr 2023 to Apr 2024
